CN103025339A - 时钟基因Period的表达调节剂 - Google Patents
时钟基因Period的表达调节剂 Download PDFInfo
- Publication number
- CN103025339A CN103025339A CN2011800172924A CN201180017292A CN103025339A CN 103025339 A CN103025339 A CN 103025339A CN 2011800172924 A CN2011800172924 A CN 2011800172924A CN 201180017292 A CN201180017292 A CN 201180017292A CN 103025339 A CN103025339 A CN 103025339A
- Authority
- CN
- China
- Prior art keywords
- oil
- gene
- expression
- extract
- period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 105
- 101150038243 CLOCK gene Proteins 0.000 title description 32
- 239000003921 oil Substances 0.000 claims abstract description 61
- 239000000284 extract Substances 0.000 claims abstract description 41
- 239000010678 thyme oil Substances 0.000 claims abstract description 21
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 claims abstract description 14
- 240000007436 Cananga odorata Species 0.000 claims abstract description 11
- 235000002566 Capsicum Nutrition 0.000 claims abstract description 11
- 239000006002 Pepper Substances 0.000 claims abstract description 11
- 235000016761 Piper aduncum Nutrition 0.000 claims abstract description 11
- 235000017804 Piper guineense Nutrition 0.000 claims abstract description 11
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 11
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims abstract description 11
- 239000010627 cedar oil Substances 0.000 claims abstract description 10
- 239000001111 citrus aurantium l. leaf oil Substances 0.000 claims abstract description 10
- 244000269722 Thea sinensis Species 0.000 claims abstract description 8
- 239000001148 ferula galbaniflua oil terpeneless Substances 0.000 claims abstract description 8
- 239000010619 basil oil Substances 0.000 claims abstract description 7
- 229940018006 basil oil Drugs 0.000 claims abstract description 7
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 claims abstract description 7
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 6
- 244000203593 Piper nigrum Species 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims description 82
- 241000209485 Nuphar Species 0.000 claims description 12
- 235000007571 Cananga odorata Nutrition 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 10
- 244000025254 Cannabis sativa Species 0.000 claims description 9
- 241000218645 Cedrus Species 0.000 claims description 9
- 230000002060 circadian Effects 0.000 claims description 8
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 6
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 6
- 235000006468 Thea sinensis Nutrition 0.000 claims description 6
- 235000020279 black tea Nutrition 0.000 claims description 5
- 235000019198 oils Nutrition 0.000 abstract description 53
- 241000721662 Juniperus Species 0.000 abstract description 3
- 229940089116 arnica extract Drugs 0.000 abstract description 3
- 244000131415 Zanthoxylum piperitum Species 0.000 abstract description 2
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 abstract description 2
- 239000001902 eugenia caryophyllata l. bud oil Substances 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 240000007891 Nuphar japonica Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000010639 cypress oil Substances 0.000 abstract 1
- 229940116257 pepper extract Drugs 0.000 abstract 1
- 239000010666 rose oil Substances 0.000 abstract 1
- 235000019719 rose oil Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 230000027288 circadian rhythm Effects 0.000 description 26
- 230000033764 rhythmic process Effects 0.000 description 22
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 16
- 235000013599 spices Nutrition 0.000 description 16
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000001105 regulatory effect Effects 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- 238000004821 distillation Methods 0.000 description 11
- 235000008216 herbs Nutrition 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 9
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 9
- 241000722363 Piper Species 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229960000890 hydrocortisone Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- -1 Bmal2) Proteins 0.000 description 6
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 210000001626 skin fibroblast Anatomy 0.000 description 6
- 101150032765 ARNTL gene Proteins 0.000 description 5
- 108010037139 Cryptochromes Proteins 0.000 description 5
- 241000949456 Zanthoxylum Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 102100040881 60S acidic ribosomal protein P0 Human genes 0.000 description 4
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 4
- 101000673456 Homo sapiens 60S acidic ribosomal protein P0 Proteins 0.000 description 4
- 241000207923 Lamiaceae Species 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000002351 wastewater Substances 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- KCYOZNARADAZIZ-CWBQGUJCSA-N 2-[(2e,4e,6e,8e,10e,12e,14e)-15-(4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-2-yl)-6,11-dimethylhexadeca-2,4,6,8,10,12,14-heptaen-2-yl]-4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-6-ol Chemical compound O1C2(C)CC(O)CC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C1C=C2C(C)(C)CCCC2(C)O1 KCYOZNARADAZIZ-CWBQGUJCSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 244000183685 Citrus aurantium Species 0.000 description 3
- 235000007716 Citrus aurantium Nutrition 0.000 description 3
- KCYOZNARADAZIZ-PPBBKLJYSA-N Cryptochrome Natural products O[C@@H]1CC(C)(C)C=2[C@@](C)(O[C@H](/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(\C)/[C@H]3O[C@@]4(C)C(C(C)(C)CCC4)=C3)/C)\C)/C)C=2)C1 KCYOZNARADAZIZ-PPBBKLJYSA-N 0.000 description 3
- 241000218691 Cupressaceae Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- KCYOZNARADAZIZ-XZOHMNSDSA-N beta-cryptochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C3OC4(C)CCCC(C)(C)C4=C3 KCYOZNARADAZIZ-XZOHMNSDSA-N 0.000 description 3
- 239000010642 eucalyptus oil Substances 0.000 description 3
- 229940044949 eucalyptus oil Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000019225 fermented tea Nutrition 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 108010088547 ARNTL Transcription Factors Proteins 0.000 description 2
- 102000008867 ARNTL Transcription Factors Human genes 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 241000717739 Boswellia sacra Species 0.000 description 2
- 241000723436 Chamaecyparis obtusa Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 2
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 2
- 235000016646 Citrus taiwanica Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 241000116713 Ferula gummosa Species 0.000 description 2
- 239000004863 Frankincense Substances 0.000 description 2
- 101150027313 Has2 gene Proteins 0.000 description 2
- 235000008694 Humulus lupulus Nutrition 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001529734 Ocimum Species 0.000 description 2
- 235000011449 Rosa Nutrition 0.000 description 2
- 235000016588 Rosa centifolia Nutrition 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000001444 canarium indicum l. oil Substances 0.000 description 2
- 239000010628 chamomile oil Substances 0.000 description 2
- 235000019480 chamomile oil Nutrition 0.000 description 2
- 230000008632 circadian clock Effects 0.000 description 2
- 239000001939 cymbopogon martini roxb. stapf. oil Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012207 quantitative assay Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000004215 skin function Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- QEOSCXACXNFJCY-AKHDSKFASA-N (2R,3R,4S,5R)-6-benzyl-7-phenylheptane-1,2,3,4,5,6-hexol Chemical compound C(C1=CC=CC=C1)C(O)([C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CC1=CC=CC=C1 QEOSCXACXNFJCY-AKHDSKFASA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical class CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MFKRHJVUCZRDTF-UHFFFAOYSA-N 3-methoxy-3-methylbutan-1-ol Chemical compound COC(C)(C)CCO MFKRHJVUCZRDTF-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 241001081440 Annonaceae Species 0.000 description 1
- 241000208983 Arnica Species 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000218646 Cedrus deodara Species 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000723198 Cupressus Species 0.000 description 1
- 244000235531 Cupressus funebris Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000973177 Homo sapiens Nuclear factor interleukin-3-regulated protein Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- 241000592238 Juniperus communis Species 0.000 description 1
- 241000981924 Juniperus oxycedrus Species 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010701 Lavanda vera Nutrition 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 241000604742 Machilus thunbergii Species 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101150087839 Npas2 gene Proteins 0.000 description 1
- 244000108404 Nuphar japonicum Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000011205 Ocimum Nutrition 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 240000005860 Portulaca grandiflora Species 0.000 description 1
- 244000052585 Rosa centifolia Species 0.000 description 1
- 240000004978 Rosa x damascena Species 0.000 description 1
- UQVUEULZDJRMJR-UHFFFAOYSA-N Sempervirine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C=C1CCCCC1=C2 UQVUEULZDJRMJR-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241001310394 Zanthoxylum piasezkii Species 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002386 air freshener Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229910002056 binary alloy Inorganic materials 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000001098 delayed sleep phase syndrome Diseases 0.000 description 1
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 208000013651 non-24-hour sleep-wake syndrome Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000005418 vegetable material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000002166 wet spinning Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了能有效调节Period基因的表达的物质,其具有广泛的应用。所述Period基因的表达调节剂包含作为活性成分的一种或多种选自以下的物质:阿尼菊提取物、日本萍蓬草提取物、黑茶提取物、花椒提取物、刺柏油、雪松油、熏衣草油、丁香花蕾油、柏木油、玫瑰油、依兰油、格蓬油、卑柠油、胡椒油、百里香油、罗勒油和β-石竹烯。
Description
发明领域
本发明涉及时钟基因的表达调节剂,更具体涉及时钟基因Period的表达调节剂及包含所述表达调节剂的昼夜节律调节剂。
相关领域描述
地球上几乎所有的活的生物体都具有内在的“生物钟”,其在约24小时的周期内自主地波动。生物钟引起称为昼夜节律的生物学上的每日波动,其被认为控制多种生物学现象(活性)的昼间变化,所述生物学现象不仅包括生物的睡-醒周期,还包括体温、血压、激素分泌、新陈代谢、以及心理活动和身体活动、进食等。近年来已指出昼夜节律紊乱是多种心身症状(psychosomatic symptom)或疾病状况(包括睡眠障碍、皮肤疾病、与生活方式有关的疾病和神经精神障碍诸如抑郁等)的致病因素。
如图1中所阐明,生物钟由节律产生***控制,所述***包括一组称为“时钟基因”的基因。在哺乳动物中时钟的分子机制的核心是由编码四个蛋白质CLOCK、BMAL1、PERIOD和CRYPTOCHROME的基因的转录的促进/抑制所组成的反馈回路。昼夜节律由该反馈回路的波动产生,周期为约24小时。
虽然昼夜节律的控制中心(中枢时钟)位于下丘脑中的视交叉上核,但已经变得清楚的是时钟基因甚至在肝、肾、皮肤和其他的外周组织中表达,在其中通过相似的***产生昼夜节律。外周的时钟基因的表达通过来自视交叉上核的信号调节。已经进一步证实外周组织和细胞中的时钟基因的表达直接受信号刺激因子如糖皮质激素、儿茶酚胺、血管紧张素II和其它信号刺激因子控制以产生生理节律。近年来,通过在体外使用刺激因子如糖皮质激素、福斯高林、血清和其它刺激因子诱导时钟基因表达的昼夜节律,以同步表达节律,并通过使用它们的表达作为标准评价昼夜节律,对培养细胞诸如成纤维细胞的昼夜节律进行了研究(非专利文件1、2和3)。
时钟基因直接控制作为转录因子的其他基因的表达节律,并通过调节激素分泌等间接控制更多的基因的昼间表达。已经变得清楚的是生物中时钟基因的表达节律的破坏引起身体器官或内分泌***的问题,其导致多种疾病,包括与生活方式有关的疾病诸如高血压(非专利文件4)。例如,已报导患有肥胖症的人显示时钟基因的异常表达,还报道了与抑郁和癌症的关联性。另外,已经阐明时钟基因调节皮肤的多种生理功能的昼夜节律。在使用正常人皮肤成纤维细胞的试验中,报道了I型胶原基因以昼夜节律表达,其表达模式与时钟基因Period 2的表达模式相似(非专利文件5)。
通过调节时钟基因的表达,调整受时钟基因控制的活的生物体的多种行为节律和生理功能的昼夜节律是可能的。因此对开发能调节时钟基因的表达的活性剂有强烈的需求。
[非专利文件1]
H.Okamura,“细胞时钟中的时钟基因:作用、功能和奥秘(ClockGenes in Cell Clocks:Roles,Actions,and Mysteries)”,Journal ofBiological Rhythms,第19卷,第5期,第388-399页,2004。
[非专利文件2]
A.Balsalobre等人,“血清性休克诱导哺乳动物组织培养细胞中昼夜节律基因的表达(A Serum Shock Induces Circadian Gene Expression inMammalian Tissue Culture Cells)”,Cell,第93卷,第929-937页,1998。
[非专利文件3]
K.Yagita等人,“在培养的成纤维细胞中的生物钟的分子机制(Molecular Mechanisms of the Biological Clock in Cultured Fibroblasts)”,Science,第292卷,第278-281页,2001。
[非专利文件4]
M.Hastings等人,“昼夜节律钟:内分泌和代谢节律的调节剂(Circadian clocks:regulators of endocrine and metabolic rhythms)”,Journal of Endocrinology,第195卷,第187-198页,2007。
[非专利文件5]
K.Izumi等人,“具有昼夜节律表达的皮肤生理基因的分析(Gaijitsurizumu wo motsu hifuseiriidennshi no tansaku)”,日本分子生物学会,第32届年会,摘要2P-0009,2009。
发明内容
鉴于上述情况,本发明的目的是提供能调节作为生物钟核心基因的Period基因的表达的活性剂。
由于本发明人已经发现某些植物提取物或精油具有诱导时钟基因Period的表达节律以及促进其表达的特性,所以发明人完成了本发明。
本发明的Period基因的表达调节剂包含作为活性成分的一种或多种选自以下的物质:阿尼菊提取物(arnica extract)、日本萍蓬草提取物(nupharextract)、黑茶提取物、花椒提取物(Zanthoxylum extract)、刺柏油(juniperoil)、雪松油(cedar oil)、熏衣草油、丁香花蕾油(clove bud oil)、柏木油、玫瑰油、依兰油、格蓬油(galbanum oil)、卑柠油、胡椒油、百里香油、罗勒油和β-石竹烯。上文提及的特定的植物提取物或精油能调节时钟基因的表达迄今为止尚未为人所知。
在本发明中基因表达的调节不仅包括基因表达的促进而且包括基因表达的节律(相或周期)的调节。
本发明的昼夜节律调节剂包含上文提及的Period基因的表达调节剂。如上所述,时钟基因直接或间接控制参与身体器官的功能和内分泌***的多种基因的昼间表达。通过调节作为生物钟核心基因的Period基因的表达,调节受所述基因控制的活的生物体的多种行为节律和生理功能的昼夜节律是可能的。
本发明所有的Period基因的表达调节剂为草药(herbal medicine)或香料。它们可通过多种施用模式诸如透皮、经口和吸入施用而应用,且可用于包括药物、医药部外品(quasi-drug)、化妆品、食品、杂货、衣物等的多种实施方案中。通过有效地调节Period基因的表达,改善多种由昼夜节律功能障碍导致的心身或皮肤症状或疾病是可能的。
而且,在本发明的Period基因的表达调节剂中,调节透明质酸合成酶(Has)基因的表达节律的那些调节剂能促进其表达,因此被认为通过调节皮肤中透明质酸产生的昼夜节律以及通过增加其产量而改善皮肤功能。
附图简述
图1是仅显示时钟基因参与的昼夜节律产生***的核心回路的示意图。
图2是显示在培养的人皮肤成纤维细胞中使用氢化可的松和福斯高林诱导时钟基因表达的昼夜节律的图。
图3是显示在培养的人皮肤成纤维细胞中受测试物质调节的时钟基因Period1的表达的图。
实施本发明的最佳模式
本发明的Period基因的表达调节剂包含作为活性成分的特定的植物提取物或精油。
能调节Period基因的表达的植物提取物包括选自阿尼菊(arnica)、日本萍蓬草(nuphar)、黑茶和花椒(Zanthoxylum)的草药提取物。关于这些草药的详细内容请参考日本化妆品成分词典(Nihon Hann-you KeshouhinGenryou Shu)第四版(YAKUJI NIPPO LIMITED)。
以上提及的草药提取物可通过通常已知的技术获得,例如,通过使用提取溶剂将植物材料(各提取物来自其中)浸渍或加热至回流、随后过滤并浓缩。通常用于提取的任何溶剂可用作提取溶剂,所述溶剂包括水、甲醇、乙醇、丙二醇、1,3-丁二醇、甘油和其他的醇类、含水醇类溶剂、氯仿、二氯乙烷、四氯化碳、丙酮、乙酸乙酯、己烷和其他的有机溶剂,这些溶剂可以单独或组合使用。使用上文提及的溶剂获得的提取物可原样使用,或者可使用吸附技术(例如经离子交换树脂或多孔聚合物(例如AmberliteXAD-2)柱)、随后用甲醇或乙醇洗脱、然后浓缩除去杂质后使用。也可使用例如,使用水/乙酸乙酯等得到的提取物。
所有的这些草药提取物可商购获得,且下文对它们中的每一个进行简述。
阿尼菊提取物(arnica extract)由菊科阿尼菊(山生阿尼菊(Arnica montana))获得,优选从阿尼菊的花用50%乙醇或类似溶剂提取得到。
日本萍蓬草提取物(nuphar extract)由日本萍蓬草根茎(日本萍蓬草(Nuphar japonicum)获得,优选从日本萍蓬草根茎用50%乙醇或类似溶剂提取得到。
黑茶提取物由茶科(Theaceae)的黑茶(普洱茶(Thea sinensis L.var.assamica))获得,优选从黑茶或茶(Thea sinensis)的叶用30%乙醇或类似溶剂提取得到。
花椒提取物(Zanthoxylum extract)由花椒果实(川陕花椒(Zanthoxylum piperitum))获得,优选从花椒果实的果皮用70%乙醇或类似溶剂提取得到。
能调节Period基因表达的植物精油(香料)包括刺柏油、雪松油、熏衣草油、丁香花蕾油、柏木油、玫瑰油、依兰油、格蓬油、卑柠油、胡椒油、百里香油、罗勒油和β-石竹烯。这些香料均是商购可得的,将其简述如下。
刺柏油是通过水蒸气蒸馏刺柏(欧洲刺柏(Juniperus communis L),该植物是柏科(Cupressacea)的常绿树)的枝和叶而获得的精油。
雪松油是通过水蒸气蒸馏雪松属(Cedrus)喜马拉雅雪松树(Himalayancedar tree)的木材而获得的精油。
熏衣草油是通过水蒸气蒸馏药用薰衣草(Lavandula officinalis)的精选的花而获得的精油,该植物为唇形科(Lamiaceae)的矮灌木。
丁香花蕾油是通过水蒸气蒸馏在开花前干燥的桃金娘科丁香(Eugenia caryophyllata)的丁香花蕾而获得的精油。
柏木油是通过水蒸气蒸馏柏木(地中海柏木(Cupressus sempervirene))的枝和叶而获得的精油。
玫瑰油是通过水蒸气蒸馏洋蔷薇(百叶蔷薇(Rosa centifoliaL))、大马士革蔷薇(突厥蔷薇(Rosa damascena Mill.))和其他蔷薇花而获得的精油。
依兰油是通过直接水蒸气蒸馏番荔枝科(Anonaceae)的植物依兰(Canning odorata)的花或者用石油醚或其他溶剂提取新鲜的花而获得的精油。
格蓬油是通过水蒸气蒸馏从格蓬(Ferula galbaniflua)的叶和芽和伞形科(Umbelliferae)相关的种的叶和芽渗出的橡胶状物质而获得的精油。
卑柠油是通过水蒸气蒸馏芸香科(Rutaceae)苦橙(bitter orange)(酸橙(Citrus aurantium))的叶和其他部分的而获得的精油。
胡椒油是通过水蒸气蒸馏胡椒(胡椒(Piper nigrum L.))的浆果而获得的精油,该植物属于胡椒科的多年生植物。
百里香油是通过水蒸气蒸馏百里香(麝香草(Thymus vulgaris L.))全植物而获得的精油,该植物是唇形科的多年生草本植物。
罗勒油是通过水蒸气蒸馏零陵香(basil)(罗勒(Ocimum basilicum L.))的全部地上部分而获得的精油,该植物是唇形科的一年生草本植物。
β-石竹烯是主要存在于桃金娘科植物诸如丁香和存在于精油诸如熏衣草油中的天然倍半萜.
本发明的Period基因的表达调节剂可包含一种或多种的上文提及的植物的提取物(草药)或精油(香料)。例如,所述表达调节剂可包含一种或多种的上文提及的草药与一种或多种的上文提及的香料的组合。
本发明的昼夜节律的调节剂包含一种或多种的作为Period基因的表达调节剂的上文提及的植物提取物或精油。
Period基因的表达调节剂可单独使用或与具有调节其它的时钟基因表达的作用的活性剂组合使用。
其它的时钟基因的实例包括Bmal基因(Bmal1、Bmal2)、Clock基因、Cryptochrome基因、白蛋白D位点结合蛋白(Dbp)基因、E4BP4基因、Npas2基因和Rev-erb基因。然而,Period基因的表达调节剂优选与Bmal、Clock和/或Cryptochrome基因、生物钟的其它核心基因的表达调节剂组合使用,尤其优选与一种或多种Bmal基因的表达调节剂组合施用。
在如图1中所示的昼夜节律的节律-产生***中,BMAL1(Bmal基因的表达产物)与CLOCK形成异源二聚体以促进Period基因的转录,而表达的PERIOD(PER)与CRYPTOCHROME(CRY)形成异源二聚体以抑制BMAL和CLOCK活性,由此形成在24小时期间波动的反馈回路。在哺乳动物中,Bmal和Period基因的昼夜节律波动的相转换时间约12小时。Bmal表达在夜间增加,而Period表达在白天增加。因此认为经由Period和Bmal基因二者的表达的调节可调节生物钟的核心回路,从而可更有效地调节昼夜节律。
Bmal基因的表达调节剂包括但不限于草药诸如,日本扁柏(hinokicypress)、小球藻(chlorella)、酒花(hop)、花椒(Zanthoxylum)和其它的提取物;和香料诸如,刺柏油、熏衣草油、桉树油、乳香、柏木油、玫瑰草油、松针油、玫瑰油、依兰油、榄香油、卑柠油(petitgrain oil)、胡椒油(pepperoil)、百里香油和春黄菊油和其它的精油。已确认这些草药或香料能在培养的皮肤成纤维细胞中诱导Bmal基因的表达节律或促进其表达。
此外,Period基因的表达调节剂和本发明的昼夜节律调节剂可单独使用或可包含在各种不同的物体中。根据物体的种类,所述物体可补充地包含任何成分以及上文提及的必需成分。
例如,当所述物体为应用于皮肤的外用制剂,根据其剂型(例如液体制剂、粉末制剂、颗粒剂、气雾剂、固体制剂、凝胶剂、贴剂、栓剂等)或其产品形式(例如化妆品、药物、医药部外品等)可包含通常存在于这样的外用制剂中的任何成分以及上文提及的Period基因的表达调节剂。应用于皮肤的外用制剂包括通常应用于皮肤(包括头部皮肤、头发和指甲)的组合物,且包括化妆品诸如护肤品、美容品、护发产品、洗面产品、洗发产品等,以及各种药物和医药部外品诸如软膏剂、贴剂、栓剂、牙膏等。所述剂型包括但不限于基于水的***、增溶***、乳剂、基于油的***、凝胶剂、糊剂、软膏剂、气雾剂、水-油两相***、水-油-粉末三相***等。当应用于皮肤的外用制剂为化妆品时,其包括香水、淡香水(eaux de toilet)、古龙香水(eaux de cologne)、霜、乳状液、化妆水、粉底化妆品、擦脸粉、唇膏、肥皂、洗发剂和护发素、沐浴露(body shampoo)、沐浴乳(body rinse)、爽身粉、浴皂等。
本发明的Period基因的表达调节剂可包含在空气清新剂、除臭剂、芳香蜡烛、香(incense)、文具、钱包、包、鞋和任何其它的杂货;内衣、全套服装(outfit)、帽子、长袜、短袜和任何其它衣物中;或在粉末、颗粒剂、胶囊剂和多种其他制剂中作为食物补充剂;和在零食、饮料和任何其它食品中。此外,当本发明的Period基因的表达调节剂包含上文提及的精油(香料)时,其可用于吸入剂诸如药物吸入产品和雾化剂中,只要本发明产生其作用即可。
在本说明书中举例阐述了本发明的Period基因的表达调节剂的实施方案。然而本发明不仅限于说明书中描述的实施方案,而且可采用于任何应用模式,条件是产生本发明的作用。根据具体的应用模式,可将具有调节昼夜节律作用的其它活性剂与本发明的Period基因的表达调节剂组合,条件是不妨碍本发明的作用。
在物体中的本发明的Period基因的表达调节剂的含量不被特别限制,且可根据所用的草药或香料的种类和形式、该物体等适当地进行选择,例如为该物体的总质量的0.00001质量%至100质量%、优选0.0001质量%至50质量%、且更优选0.0001质量%至20质量%。
本发明的Period基因的表达调节剂或昼夜节律的调节剂以及包含所述调节剂的物体的具体应用不被特别限制,只要与昼夜节律的调节相关即可。例如,其可应用于飞行时差反应综合征、轮班制工作综合征(shift worksyndrome)、睡眠时相延迟综合征、非24小时型睡眠-觉醒障碍、与昼夜节律睡眠障碍有关的抑郁等、以及失眠、身体状况不佳(poor physicalconditions)、注意力缺陷、情感淡漠(apathy)、皮肤粗糙(rough skin)和各种其它的与昼夜节律失调相关的症状的预防、改善、治疗等。
[实施例]
下文将使用实施例详细叙述本发明,但本发明不限于这些实施例。皮肤成纤维细胞、上皮细胞、内皮细胞、色素细胞、脂肪细胞、神经细胞和各种其它类型的细胞可用作培养细胞。然而在实施例中使用人皮肤成纤维细胞进行评价。因为时钟基因的核心***是所有物种的生物和所有类型的细胞所共有的,所以认为由人皮肤成纤维细胞得到的评价结果应当可适用于其它物种的生物和其它类型的细胞。在人类中,三种基因被称为Period基因:Period1、Period2和Period3。由于它们属于同一基因家族,所以认为它们的表现相似。在以下的实施例中,以Period1表达作为代表进行测定。
对于使用培养的人皮肤成纤维细胞的时钟基因表达节律的评价***的
研究
已证实能在使用培养的人皮肤成纤维细胞的***中评价时钟基因表达节律。
购买了来自正常人皮肤的成纤维细胞作为培养的人成纤维细胞(CellApplication,Inc.)并将其用于试验中。将它们接种于DMEM培养基(补充有10%FBS、20mM HEPES、Glutamax和抗菌剂)中,并在37°C、5%CO2条件下培养。在培养的第6天,将50ng/mL氢化可的松或10μM福斯高林添加至各孔中,并在0时间后的多个时间点收获各样品,所述0时间定义为一经添加氢化可的松或福斯高林后的时间。使用商购可得的RNA提取试剂盒从细胞提取RNA,并使用商购可得的PCR引物(Perfect RealTime Primer,Takara Bio)通过RT-PCR技术测定目标基因的表达的量。对于时钟基因,测定Period1和Bmal1(它们包括在所述核心***中)的表达的量。相似地,定量测定管家基因RPLP0的表达的量,并用作内标准以计算目标基因相对于RPLP0的表达。
在活的生物体中,糖皮质激素诸如氢化可的松与在外周组织等中调节生物钟相关,而且认为当在早上觉醒时,氢化可的松的血液浓度升高以重置生物钟。在培养的细胞中,单独的细胞通常独立地保持它们的节律。通过使用信号刺激因子诸如氢化可的松或福斯高林进行刺激能同步时钟基因的表达节律以诱导昼夜节律。
结果在图2中显示。证实了Period1和Bmal1表达分别在刺激后约2小时和约16小时出现高峰,且这两种基因均以约24小时周期的昼夜节律循环表达。
测试物质对Period基因的表达调节作用的评价
使用培养的人皮肤成纤维细胞的评价***的以上提及的结果证明Period1显示了在使用试剂刺激后约2小时具有基因表达的高峰的昼夜节律。基于在刺激后2小时的基因表达的量评价测试物质对Period基因的表达调节作用。为证实对Period基因的表达节律的诱导,还测定了Period1基因在刺激后16小时的表达的量。
根据与上文所使用的相似的方法接种来自正常人皮肤的成纤维细胞(Cell Application,Inc.)。在培养的第6天加入各个测试物质,最终浓度100ppm,并在刺激后2和16小时收获细胞。使用商购可得的RNA提取试剂盒从细胞提取RNA。使用商购可得的PCR引物(Perfect Real Time Primer,Takara Bio)通过RT-PCR技术测定Period1基因的表达的量。
此外,还针对透明质酸合成酶(HAS)类似地测定了基因表达,透明质酸合成酶与透明质酸的生成相关,透明质酸在保持皮肤水分方面起重要作用。HAS1、HAS2和HAS3被称为HAS,且将HAS2作为透代表性的明质酸合成酶进行了测定。
定量测定管家基因RPLP0的基因表达的量,并将其用作内标准以计算目标基因相对于RPLP0的相对表达。对得到的各测定结果进行Dunnett的多重比较检验,与对照相比具有单向的5%的显著性水平的测定结果被认定为是显著有效的。
图3显示在添加各种测试物质和作为阳性对照的氢化可的松或福斯高林2和16小时后Period1基因的基因表达的相对量。
以下表1显示在刺激后2小时Period1基因的基因表达的相对量。对于一些测试物质,在刺激后16小时Has2基因的基因表达的相对量也显示表1中。
[表1]
*:p<0.05,**:p<0.01
已证实阿尼菊提取物、日本萍蓬草提取物、黑茶提取物、花椒提取物、刺柏油、雪松油、熏衣草油、丁香花蕾油、柏木油、玫瑰油、依兰油、格蓬油、卑柠油、胡椒油、百里香油、罗勒油和β-石竹烯、以及阳性对照氢化可的松和福斯高林能够诱导在刺激后2小时具有高峰的表达节律,并显著地增加Period1基因表达的量,因此这些草药或香料能够调节Period基因的表达。
另外,还提示了刺柏油、依兰油和胡椒油能够通过增加透明质酸生成而改善或增进皮肤功能,原因是它们被证明在刺激后16小时促进Has2基因表达。
本发明的Period基因的表达调节剂可与Bmal基因的表达调节剂组合使用,所述Bmal基因的表达调节剂包括但不限于草药诸如日本扁柏(hinokicypress)、小球藻(chlorella)、酒花(hop)、花椒(Zanthoxylum)和其它的提取物;和香料,诸如刺柏油、熏衣草油、桉树油、乳香、柏木油、玫瑰草油、松针油、玫瑰油、依兰油、榄香油、卑柠油、胡椒油、百里香油、春黄菊油和其它精油。通过在培养的皮肤成纤维细胞中使用Bmal1作为代表检测Bmal基因的表达节律,已证实这些草药或香料能够诱导Bmal基因的表达节律或促进其表达。下表2显示在刺激后16小时Bmal1基因的基因表达的相对量。
[表2]
*:p<0.05,**:p<0.01
(组合物实施例)
下文给出本发明的Period基因的表达调节剂的组合物实施例,但本发明不限于以下所述内容。在下文的组合物实施例中,将百里香油用作本发明的Period基因的表达调节剂。可包含上文所述的能调节Period基因的表达的草药和/或香料中的一种或超过一种的混合物。组合量均以相对于各产品的总量的质量百分比表示。
[香料]
(1)酒精 75.0
(2)净化水 剩余部分
(3)双丙二醇 5.0
(4)本发明的Period基因的表达调节剂(百里香油) 10.0
(5)抗氧化剂 8.0
(6)色素 适量
(7)紫外线吸收剂 适量
[房间清新剂]
(1)酒精 80.0
(2)净化水 剩余部分
(3)抗氧化剂 5.0
(4)本发明的Period基因的表达调节剂(百里香油) 3.0
(5)3-甲基-3-甲氧基丁醇 5.0
(6)二亚苄基山梨醇 5.0
[香]
(1)Makko粉 75.5
(2)苯甲酸钠 15.5
(3)本发明的Period基因的表达调节剂(百里香油) 5.0
(4)桉树油 1.0
(5)净化水 剩余部分
[浴盐]
(1)硫酸钠 45.0
(2)碳酸氢钠 45.0
(3)熏衣草油 9.0
(4)本发明的Period基因的表达调节剂(百里香油) 1.0
[按摩凝胶]
(1)赤藓糖醇 2.0
(2)咖啡因 5.0
(3)黄柏(Phellodendron amurense)树皮提取物 3.0
(4)甘油 50.0
(5)聚羧乙烯 0.4
(6)聚乙二醇400 30.0
(7)依地酸三钠 0.1
(8)聚氧乙烯(10)甲基聚硅氧烷共聚物 2.0
(9)角鲨烷 1.0
(10)氢氧化钾 0.15
(11)本发明的Period基因的表达调节剂(百里香油) 1.0
[按摩霜]
(1)固体石蜡 5.0
(2)蜂蜡 10.0
(3)凡士林 15.0
(4)液体石蜡 41.0
(5)1,3-丁二醇 4.0
(6)单硬脂酸甘油酯 2.0
(7)POE(20)脱水山梨醇单月桂酸酯 2.0
(8)硼砂 0.2
(9)咖啡因 2.0
(10)防腐剂 适量
(11)抗氧化剂 适量
(12)本发明的Period基因的表达调节剂(百里香油) 1.0
(13)净化水剩 余部分
[芳香型纤维]
将含本发明的Period基因的表达调节剂的微囊剂(颗粒直径:不大于50μm(微米);微囊剂中精油的百分比:50重量%)以纤维素重量的0.1重量%至20重量%添加至铜铵纤维素(cuproammonium cellulose)溶液(纤维素浓度:10重量%;铵浓度:7重量%;铜浓度:3.6重量%)中,将其混合,并通过常规的湿纺法纺丝,在精制步骤和干燥步骤后,得到芳香型纤维。
[颗粒剂]
(1)三氯蔗糖 0.1
(2)本发明的Period基因的表达调节剂(百里香油) 0.1
(3)矫味剂 5.0
(4)赋形剂(Ceolus) 10.0
(5)麦芽糖醇 剩余部分
[片剂(咀嚼型)]
(1)肌醇 11.0
(2)麦芽糖醇 21.0
(3)蔗糖 0.5
(4)鲑鱼精提取物(DNA Na) 0.1
(5)酵母提取物 0.1
(6)本发明的Period基因的表达调节剂(百里香油) 0.1
(7)矫味剂 5.0
(8)赋形剂 剩余部分
[片剂]
(1)滑润剂(蔗糖脂肪酸酯等) 1.0
(2)***胶水溶液(5%) 2.0
(3)酸化剂 1.0
(4)着色剂 适量
(5)本发明的Period基因的表达调节剂(百里香油) 0.1
(6)糖(糖粉、山梨糖等) 剩余部分
[糖果]
(1)食糖 50.0
(2)淀粉糖浆 47.95
(3)有机酸 2.0
(4)本发明的Period基因的表达调节剂(百里香油) 0.05
[口胶剂]
(1)食糖 43.0
(2)胶基(Gum base) 30.95
(3)葡萄糖 10.0
(4)淀粉糖浆 16.0
(5)本发明的Period基因的表达调节剂(百里香油) 0.05
通过以典型的应用方式试验性使用各产品形式,这些组合物实施例的产品能够调节Period基因的表达和调节活的生物体的昼夜节律。
Claims (2)
1.昼夜节律的调节剂,其包含作为活性成分的一种或多种选自以下的物质:阿尼菊提取物、日本萍蓬草提取物、黑茶提取物、花椒提取物、刺柏油、雪松油、熏衣草油、丁香花蕾油、柏木油、玫瑰油、依兰油、格蓬油、卑柠油、胡椒油、百里香油、罗勒油和β-石竹烯。
2.Period基因的表达调节剂,其包含作为活性成分的一种或多种选自以下的物质:阿尼菊提取物、日本萍蓬草提取物、黑茶提取物、花椒提取物、刺柏油、雪松油、熏衣草油、丁香花蕾油、柏木油、玫瑰油、依兰油、格蓬油、卑柠油、胡椒油、百里香油、罗勒油和β-石竹烯。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010083017 | 2010-03-31 | ||
JP083016/2010 | 2010-03-31 | ||
JP083017/2010 | 2010-03-31 | ||
JP2010083016 | 2010-03-31 | ||
PCT/JP2011/001941 WO2011122041A1 (ja) | 2010-03-31 | 2011-03-30 | 時計遺伝子Periodの発現調節剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103025339A true CN103025339A (zh) | 2013-04-03 |
CN103025339B CN103025339B (zh) | 2015-06-17 |
Family
ID=44711796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180017292.4A Active CN103025339B (zh) | 2010-03-31 | 2011-03-30 | 时钟基因Period的表达调节剂 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20130022692A1 (zh) |
EP (1) | EP2554178B1 (zh) |
JP (1) | JP5868313B2 (zh) |
KR (1) | KR101770706B1 (zh) |
CN (1) | CN103025339B (zh) |
ES (1) | ES2567160T3 (zh) |
HK (1) | HK1183450A1 (zh) |
TW (1) | TWI552756B (zh) |
WO (1) | WO2011122041A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104519894A (zh) * | 2012-08-10 | 2015-04-15 | 株式会社资生堂 | 丝聚蛋白基因表达促进剂 |
CN105491896A (zh) * | 2013-08-27 | 2016-04-13 | 三得利控股株式会社 | 时钟基因的表达量调整剂 |
CN110305956A (zh) * | 2019-08-09 | 2019-10-08 | 北京大学 | 影响抑郁行为或抗抑郁行为的主效标记及其应用 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013046272A1 (ja) * | 2011-09-29 | 2013-04-04 | 株式会社 資生堂 | 時計遺伝子およびヒアルロン酸合成酵素遺伝子発現促進剤 |
JPWO2013046272A1 (ja) * | 2011-09-29 | 2015-03-26 | 株式会社 資生堂 | 時計遺伝子およびヒアルロン酸合成酵素遺伝子発現促進剤 |
JP2013184921A (ja) * | 2012-03-07 | 2013-09-19 | Shiseido Co Ltd | 時計遺伝子の発現調節剤 |
JP5487227B2 (ja) * | 2012-03-09 | 2014-05-07 | 株式会社 資生堂 | ヒアルロン酸合成酵素遺伝子の発現促進剤 |
DE102012205059A1 (de) * | 2012-03-29 | 2013-10-02 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen enthaltend eine oder mehrere Substanzen die das Gen für den "Krüppel-like factor 9" (Klf9) modulieren |
DE102012205066A1 (de) * | 2012-03-29 | 2013-10-02 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen enthaltend eine oder mehrere Substanzen die das Gen für den "Krüppel-like factor 9" (Klf9) modulieren |
DE102012205050A1 (de) * | 2012-03-29 | 2013-10-02 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen enthaltend eine oder mehrere Sustanzen die das Gen für den "Krüppel-like factor 9" (Klf9) modulieren |
DE102012205062A1 (de) * | 2012-03-29 | 2013-10-02 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen enthaltend eine mehere Substanzen die das Gen für den "Krüppel-like factor 9" (Klf9) modulieren |
JP6049289B2 (ja) * | 2012-04-11 | 2016-12-21 | サントリーホールディングス株式会社 | 概日リズム調整剤 |
JP2014074063A (ja) * | 2013-12-27 | 2014-04-24 | Shiseido Co Ltd | ヒアルロン酸合成酵素遺伝子の発現促進剤 |
JP6188881B2 (ja) * | 2016-07-12 | 2017-08-30 | 株式会社 資生堂 | ヒアルロン酸合成酵素遺伝子発現促進剤 |
KR102070391B1 (ko) * | 2018-05-10 | 2020-01-29 | 오세웅 | 화초 열매 추출물을 포함하는 입술 화장료 조성물 |
KR20220152560A (ko) * | 2020-03-10 | 2022-11-16 | 갓코 호진 긴키 다이가쿠 | 카리오필렌을 함유하는 제제, 조성물 및 각종 용도 |
KR102607662B1 (ko) | 2021-04-08 | 2023-12-01 | 재단법인대구경북과학기술원 | 시계 유전자 Period의 발현 억제용 단일 가이드 RNA 조합, 및 이의 용도 |
WO2024106205A1 (ja) * | 2022-11-16 | 2024-05-23 | 株式会社豊田中央研究所 | 体内時計調整剤 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006034177A (ja) * | 2004-07-27 | 2006-02-09 | Hirose Yukihiro | 安眠を促進する作用を有する飲料 |
JP2007197334A (ja) * | 2006-01-24 | 2007-08-09 | Lion Corp | 自律神経調整剤、睡眠改善剤又はストレス緩和剤用組成物 |
WO2008044046A1 (en) * | 2006-10-13 | 2008-04-17 | Reckit Benckiser (Uk) Limited | Perfume compositions |
JP2008266319A (ja) * | 2007-03-29 | 2008-11-06 | Ezaki Glico Co Ltd | 概日リズム調整組成物 |
CN101327329A (zh) * | 2008-06-25 | 2008-12-24 | 海信科龙电器股份有限公司 | 一种含有挥发性成分的植物提取物组合物 |
JP2009132662A (ja) * | 2007-11-30 | 2009-06-18 | Maruzen Pharmaceut Co Ltd | グルタチオン産生促進剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003342123A (ja) * | 2002-05-31 | 2003-12-03 | Ichimaru Pharcos Co Ltd | コラゲナーゼ活性阻害剤、エラスターゼ活性阻害剤及び化粧料組成物 |
JP2003342184A (ja) * | 2002-05-31 | 2003-12-03 | Ichimaru Pharcos Co Ltd | ヒアルロニダーゼ活性阻害剤及び化粧料組成物 |
JP2004051486A (ja) * | 2002-07-16 | 2004-02-19 | Pola Chem Ind Inc | 熱産生交感神経活性化剤 |
US20070086972A1 (en) * | 2005-09-12 | 2007-04-19 | Jacob Birnbaum | Hair growth compositions and methods for treating hair loss or related conditions |
JP2007277149A (ja) * | 2006-04-06 | 2007-10-25 | Kao Corp | インボルクリン発現促進剤 |
JP2007320956A (ja) * | 2006-05-01 | 2007-12-13 | Uha Mikakuto Co Ltd | 動脈硬化抑制剤 |
JP4598740B2 (ja) * | 2006-09-22 | 2010-12-15 | 株式会社ファンケル | グルタチオン増強用組成物 |
JP2009084216A (ja) * | 2007-09-28 | 2009-04-23 | Maruzen Pharmaceut Co Ltd | Atp産生促進剤および表皮細胞賦活化剤。 |
-
2011
- 2011-03-30 WO PCT/JP2011/001941 patent/WO2011122041A1/ja active Application Filing
- 2011-03-30 EP EP11762283.7A patent/EP2554178B1/en active Active
- 2011-03-30 KR KR1020127028529A patent/KR101770706B1/ko active IP Right Grant
- 2011-03-30 JP JP2012508101A patent/JP5868313B2/ja active Active
- 2011-03-30 ES ES11762283.7T patent/ES2567160T3/es active Active
- 2011-03-30 US US13/638,633 patent/US20130022692A1/en not_active Abandoned
- 2011-03-30 CN CN201180017292.4A patent/CN103025339B/zh active Active
- 2011-03-31 TW TW100111422A patent/TWI552756B/zh not_active IP Right Cessation
-
2013
- 2013-09-25 HK HK13110946.9A patent/HK1183450A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006034177A (ja) * | 2004-07-27 | 2006-02-09 | Hirose Yukihiro | 安眠を促進する作用を有する飲料 |
JP2007197334A (ja) * | 2006-01-24 | 2007-08-09 | Lion Corp | 自律神経調整剤、睡眠改善剤又はストレス緩和剤用組成物 |
WO2008044046A1 (en) * | 2006-10-13 | 2008-04-17 | Reckit Benckiser (Uk) Limited | Perfume compositions |
JP2008266319A (ja) * | 2007-03-29 | 2008-11-06 | Ezaki Glico Co Ltd | 概日リズム調整組成物 |
JP2009132662A (ja) * | 2007-11-30 | 2009-06-18 | Maruzen Pharmaceut Co Ltd | グルタチオン産生促進剤 |
CN101327329A (zh) * | 2008-06-25 | 2008-12-24 | 海信科龙电器股份有限公司 | 一种含有挥发性成分的植物提取物组合物 |
Non-Patent Citations (3)
Title |
---|
常海涛等: "雪松油免疫调节活性的初步研究", 《中草药》 * |
童汉清等: "胡椒油的超临界CO_2流体萃取工艺研究", 《食品工业》 * |
谭乐和等: "不同加工方法对胡椒精油化学成分的影响", 《热带作物学报》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104519894A (zh) * | 2012-08-10 | 2015-04-15 | 株式会社资生堂 | 丝聚蛋白基因表达促进剂 |
CN104519894B (zh) * | 2012-08-10 | 2018-11-09 | 株式会社资生堂 | 丝聚蛋白基因表达促进剂 |
CN105491896A (zh) * | 2013-08-27 | 2016-04-13 | 三得利控股株式会社 | 时钟基因的表达量调整剂 |
CN110305956A (zh) * | 2019-08-09 | 2019-10-08 | 北京大学 | 影响抑郁行为或抗抑郁行为的主效标记及其应用 |
Also Published As
Publication number | Publication date |
---|---|
HK1183450A1 (zh) | 2013-12-27 |
WO2011122041A1 (ja) | 2011-10-06 |
US20130022692A1 (en) | 2013-01-24 |
ES2567160T3 (es) | 2016-04-20 |
CN103025339B (zh) | 2015-06-17 |
JPWO2011122041A1 (ja) | 2013-07-04 |
TWI552756B (zh) | 2016-10-11 |
KR101770706B1 (ko) | 2017-08-23 |
EP2554178B1 (en) | 2016-01-13 |
TW201201824A (en) | 2012-01-16 |
JP5868313B2 (ja) | 2016-02-24 |
KR20130040854A (ko) | 2013-04-24 |
EP2554178A4 (en) | 2013-08-28 |
EP2554178A1 (en) | 2013-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103025339B (zh) | 时钟基因Period的表达调节剂 | |
CN102858355B (zh) | 时钟基因Bmal的表达调节剂 | |
CN102038765B (zh) | 一种用于止痛消肿的青鹏膏药及其制备方法 | |
CN106176556A (zh) | 一种祛痘控油美白面霜 | |
CN104784507A (zh) | 一种具有多重美容功效的中药组合物及其制备方法和应用 | |
CN109662904A (zh) | 一种具有美白抗氧化功效的护肤组合物及其应用和制备方法 | |
CN102028752A (zh) | 中草药复方祛斑美白组合物及外用制剂 | |
CN102198079A (zh) | 中草药面膜 | |
CN106214592A (zh) | 毛囊营养液组合物及其制备方法 | |
CN110151639A (zh) | 一种含白花蛇舌草的祛痘霜及其制备方法 | |
CN109303724A (zh) | 一种新型含艾叶的舒缓修护原液组合物 | |
CN103505398B (zh) | 一种连翘叶面膜 | |
KR101435679B1 (ko) | 피부 보습 및 주름 개선용 조성물 | |
CN103655382A (zh) | 一种用于痤疮色素沉着的复方精油 | |
CN110141542B (zh) | 一种含太子参的舒敏剂及其制备方法 | |
CN103340808A (zh) | 一种三七药物晚霜的制备工艺 | |
CN103565722A (zh) | 金耳提取物和银耳提取物的组合在化妆品中的应用 | |
JP6629271B2 (ja) | Endo180産生促進剤 | |
KR20090077619A (ko) | 주름개선에 효과가 있는 한방추출물을 포함하는 화장료조성물 | |
KR20170064671A (ko) | 허브환 및 그 제조방법 | |
CN111449998A (zh) | 一种植萃防脱生发液及其制备方法 | |
WO2015006897A1 (zh) | 一种乌发中药制剂的配方及制备方法 | |
CN108743465A (zh) | 中药凝胶组合物及其制备方法和用途 | |
CN105326693A (zh) | 一种具有生发功能的香水及其制备方法 | |
CN104490705A (zh) | 一种泡脚液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1183450 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1183450 Country of ref document: HK |